CanaQuest Medical Corp Overview
– a clinical-stage life sciences company
CanaQuest Medical (CANQF), a clinical-stage, life sciences company, is focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company is prioritizing treating neurological conditions such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder “PTSD,” including addiction.
CanaQuest is partnered for industry research and product development with Dr. Steven Laviolette, a professor and neuroscientist, with decades of experience in the field of mental health and cannabinoids, at Western University.
CanaQuest’s mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies.
New Pathway Discovery into the Brain for Mental Health: Pre-clinical trials and Clinical Studies
CQ-001 – Drug candidate formula of two APIs – cannabidiol “CBD” + essential fatty acids
• Molecules bond and synergistically attach to PPAR receptors allowing CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and NOTE: CBD by itself DID NOT do this in their pre-clinical trial research.
CQ-001 demonstrated 40% more seizure reduction compared to standard CBD from a Clinical Dose & Efficacy Study (“Study”) conducted at the Ontario Brain Institute by Dr. W McIntyre Burnham
• These results set the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects and will define a dosage of CQ-001 for a clinical trial (Phase II/III, double-blind trial, 60 patients).
US-FDA: Eligible for Orphan Drug Status & Priority Review Voucher (PRV) – projected approval in 3 years.
Health Canada: Eligible for Priority Review Status – projected approval of drug is 18 to 24 months.
Nutraceutical: An OTC (less potent version) of CQ-001, branded as Mentanine®, targeting anxiety, depression, and PTSD (without claims), is available for sale via CanaQuest Store in the US.
Neeka Health: The Company signed a Master Service Agreement with Neeka Health which will encompass multiple studies on former professional athletes. The Neeka team has conducted extensive due diligence on 97 companies and CanaQuest was the only company chosen.
Dr. Hunter Land, CSO of Neeka, who co-led the clinical development of Epidiolex® (FDA approved prescription CBD) for GW Pharma will lead all studies for Neeka and CanaQuest.
• The first study will target anxiety as the primary endpoint and depression, sleep, and quality of life for secondary endpoints.
Animal Health and Pet Market: The Company is working with Dr. Paul Dick, Paul Dick & Associates. Dr. Dick has agreed to be Head Advisor for the development of our veterinary pharmaceutical business, as well as advising on veterinary regulatory strategies to obtain approvals from regulatory authorities.
CanaQuest has been named: 2022 Global Excellence Awards, Best Medical Cannabis and Botanical Oils Product Development Company, North America – awarded by Global Health & Pharma, UK.
Paul Ramsay, President & Co-founder
cell: 416-704-3040 paul@canaquest.com www.canaquest.com www.canaqueststore.com